Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of Fingolide in relapsing-remitting multiple sclerosis
IRCT201112267419N4Phase 4Completed
- Sponsor
- Osveh Pharmaceutical
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fingolimod in multiple sclerosis (MS), sponsored by Osveh Pharmaceutical. Started Aug 2012; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT201112267419N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201112267419N4.